AbbVie Director Jennifer L. Davis Resigns Following Appointment as Align Technology CEO
AbbVie Inc.
Subscribe to track ABBV
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
AbbVie Inc. ($ABBV) - Form 8-K Filing Event: Director Resignation (Item 5.02) Director: Jennifer L. Davis (Class II Director) Effective Date: November 2, 2026 Reason: Stepping down due to appointment as Chief Executive Officer at Align Technology, Inc. Disagreements: None reported.
Comprehensive Analysis
Executive Summary
On November 2, 2026, AbbVie Inc. filed a Form 8-K under Item 5.02 announcing the resignation of Class II Director Jennifer L. Davis from the Board of Directors, effective November 2, 2026.
Key Details
- Notification Date: October 28, 2026
- Effective Date: November 2, 2026
- Reason for Departure: Ms. Davis resigned in light of her recent appointment as Chief Executive Officer at Align Technology, Inc.
- Disagreements/Disputes: The filing specifies that her resignation is not due to any dispute or disagreement with AbbVie Inc. regarding its operations, policies, or practices.
Market & Governance Impact
This departure is categorized as having Low trading significance. It is an orderly resignation prompted by new external executive obligations at another public company rather than internal friction, accounting discrepancies, or governance controversies.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.